Press Releases

 11 Jul, 2023, 07:30 ET  $4.1 million in Gross Product Revenue 20% growth over 3Q23; 78% growth over 4Q22 $1.7 million in Net Product Revenue 42% growth over 3Q23; 122% growth over 4Q22 14% growth in prescriptions dispensed over 3Q23; 89% growth over 4Q22 6 consecutive quarters of double-digit growth 20% growth in new healthcare […]

–  Results demonstrate melanocortin agonists may represent a new therapeuticavenue to treat diabetic nephropathy –  Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

 May 16, 2023, 07:30 ET  Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability Final Data Expected Second Half Calendar Year

 May 11, 2023, 16:15 ET  CRANBURY, N.J., May 11, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

 May 09, 2023, 07:30 ET  –  Preclinical data presented shows PL8177 was found to be efficacious in animal models of inflammatory bowel disease –  Clinical data confirms PL8177 oral formulation is delivered and contained in the colon –  Phase 2 clinical study data readout in 2H2023 CRANBURY, N.J., May 9, 2023 /PRNewswire/ — Palatin Technologies,

 May 08, 2023, 16:04 ET  CRANBURY, N.J., May 8, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader (KOL) webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase

 May 01, 2023, 16:00 ET  – Review of Phase 3 PL9643 Data for Dry Eye Disease – Data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease – Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET CRANBURY, N.J., May 1, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American:

 Apr 27, 2023, 07:30 ET  – Poster data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease – Consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile – Melody-1 Phase 3 clinical study continuing patient enrollment – final data

 Apr 25, 2023, 07:30 ET  –  Poster presented at ARVO demonstrates PL9588 reduces intraocular pressure –  Data provides further support for topical administration of melanocortins for ocular inflammation CRANBURY, N.J., April 25, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced

 Apr 19, 2023, 07:30 ET  $3.4 million in Gross Product Revenue 31% growth over 2Q23; 165% growth over 3Q22 $1.2 million in Net Product Revenue 22% growth over 2Q23; 469% growth over 3Q22 27% growth in prescriptions dispensed over 2Q23; 147% growth over 3Q22 5 consecutive quarters of double-digit growth CRANBURY, N.J., April 19, 2023